Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

Historical Holders from Q3 2019 to Q3 2025

Symbol: MIRM on Nasdaq
Type / Class: Equity / Common Stock
Shares outstanding: 51,368,292
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 57,250,607
Holdings value: $4,197,040,984
% of all portfolios: 0.007%
Number of holders: 266
Number of buys: 160
Number of sells: -91
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
JANUS HENDERSON GROUP PLC	10.6%	+6%	$388,340,181	+$31,912,348	5,445,039	+9%	JANUS HENDERSON GROUP PLC	28 Nov 2025
Frazier Life Sciences IX, L.P.	7.4%	0%	$273,828,978		3,735,220	0%	James N. Topper	01 Nov 2025
EVENTIDE ASSET MANAGEMENT, LLC	5.43%		$107,692,609		2,606,938		Eventide Asset Management, LLC	31 Dec 2024
BIOTECHNOLOGY VALUE FUND L P	3%		$109,619,710		1,495,290		BVF PARTNERS L P/IL	30 Sep 2025

Institutional Holders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	57,250,607	$4,197,040,984	+$132,882,990	$7,712,212	$6,311,991	$73.31	266
2025 Q2	55,393,029	$2,819,019,204	+$70,434,976	$5,033,021	$1,287,517	$50.89	211
2025 Q1	54,142,705	$2,443,759,313	+$49,081,267	$4,725,745	$1,234,370	$45.05	213
2024 Q4	52,986,109	$2,190,964,431	-$26,045,809	$4,122,595	$107,510	$41.35	204
2024 Q3	53,301,609	$2,079,251,226	-$2,890,149	$6,524,700	$6,910,800	$39	176
2024 Q2	53,362,791	$1,824,471,702	+$17,964,526	$1,873,612	$2,943,759	$34.19	157
2024 Q1	53,243,448	$1,337,601,222	+$70,337,692	$1,499,664	$1,507,200	$25.12	167
2023 Q4	50,259,606	$1,483,847,413	+$1,676,068	$1,974,888	$876,744	$29.52	184
2023 Q3	48,930,333	$1,545,592,030	+$398,674,334	$1,380,920	$1,365,120	$31.6	156
2023 Q2	36,937,639	$955,518,729	+$63,103,719	$822,666	$380,289	$25.87	143
2023 Q1	34,669,406	$832,753,531	+$33,992,984	$84,070	$482,802	$24.02	114
2022 Q4	33,331,988	$650,146,380	-$12,725,497	$136,500	$421,200	$19.5	101
2022 Q3	33,748,714	$709,089,633	+$93,197,315	$0	$370,000	$21.01	107
2022 Q2	29,289,263	$568,434,366	+$47,575,699	$284,000	$0	$19.46	104
2022 Q1	26,813,353	$590,437,915	-$6,195,298	$590,000	$865,000	$22.02	99
2021 Q4	22,891,220	$365,087,000	+$18,990,411	$629,000	$762,000	$15.95	81
2021 Q3	21,414,209	$426,514,254	+$2,080,056	$606,000	$1,068,000	$19.92	69
2021 Q2	21,482,092	$371,413,185	+$642,669			$17.29	66
2021 Q1	21,451,984	$425,174,000	-$8,433,468			$19.82	60
2020 Q4	22,010,623	$384,380,000	+$52,268,047			$17.46	71
2020 Q3	18,743,135	$361,180,000	-$1,290,295			$19.27	50
2020 Q2	18,808,446	$366,015,000	+$8,936,163			$19.46	57
2020 Q1	18,603,225	$260,445,000	+$32,083,278			$14	43
2019 Q4	16,248,910	$398,421,000	+$12,819,124			$24.52	39
2019 Q3	16,487,274	$165,856,000	+$165,755,000			$10.06	38